FIR

DRUG3 trials

Sponsors

Gilead Sciences, University of Palermo

Conditions

AthletesCyclistsNonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic SteatohepatitisNonalcoholic Steatohepatitis (NASH)

Phase 2

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

CompletedNCT02781584

Gilead SciencesNonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)

Start: 2016-06-13End: 2020-12-17Updated: 2022-03-16

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

CompletedNCT03449446

Gilead SciencesNonalcoholic Steatohepatitis

Start: 2018-03-21End: 2019-11-19Updated: 2020-12-03

Unknown Phase

Acute Physiological Effects of Full-Body Far-Infrared Emitting Textiles on Young Road Cyclists

CompletedNCT07503977

University of PalermoAthletes, Cyclists

Start: 2025-04-15End: 2025-06-25Updated: 2026-03-31

Related Papers

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.

2025-01-019 citations

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.

2024-08-0728 citations

Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.

2022-01-0632 citations

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Hepatology Communications2021-05-1231 citations